PE20141012A1 - Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion - Google Patents

Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion

Info

Publication number
PE20141012A1
PE20141012A1 PE2013001723A PE2013001723A PE20141012A1 PE 20141012 A1 PE20141012 A1 PE 20141012A1 PE 2013001723 A PE2013001723 A PE 2013001723A PE 2013001723 A PE2013001723 A PE 2013001723A PE 20141012 A1 PE20141012 A1 PE 20141012A1
Authority
PE
Peru
Prior art keywords
iloxi
metoxy
undecan
dimaleate
quinazolin
Prior art date
Application number
PE2013001723A
Other languages
English (en)
Inventor
Waldemar Franz Augustin Pfrengle
Gunther Nikolaus Huchler
Markus Ostermeier
Peter Sieger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20141012A1 publication Critical patent/PE20141012A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL DIMALEATO DE 9-[4-(3-CLORO-2-FLUORO-FENILAMINO)-7-METOXI-QUINAZOLIN-6--ILOXI]-1,4-DIAZA-ESPIRO[5.5]UNDECAN-5-ONA, CARACTERIZADO PORQUE SE MANIFIESTAN REFLEJOS EN EL DIAGRAMA DE POLVO DE RAYOS X CON VALORES dHKL DE 7, 11, 5, 77, 4, 69, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO PARA LA PREPARACION ESTEREOSELECTIVA DEL COMPUESTO, SIENDO UTIL DICHO COMPUESTO PARA EL TRATAMIENTO DE ENFERMEDADES INFECCIOSAS O ALERGIA DE LAS VIAS RESPIRATORIAS.
PE2013001723A 2011-02-01 2012-01-27 Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion PE20141012A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11152895 2011-02-01

Publications (1)

Publication Number Publication Date
PE20141012A1 true PE20141012A1 (es) 2014-09-10

Family

ID=43896655

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001723A PE20141012A1 (es) 2011-02-01 2012-01-27 Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion

Country Status (23)

Country Link
US (2) US8853225B2 (es)
EP (1) EP2670736B1 (es)
JP (1) JP2014504619A (es)
KR (1) KR20140011330A (es)
CN (1) CN103608336A (es)
AP (1) AP3531A (es)
AR (1) AR085056A1 (es)
AU (1) AU2012213556A1 (es)
BR (1) BR112013019416A2 (es)
CA (1) CA2826193A1 (es)
CL (1) CL2013002031A1 (es)
CO (1) CO6781555A2 (es)
EA (1) EA023573B1 (es)
EC (1) ECSP13012847A (es)
GE (1) GEP20156423B (es)
IL (1) IL227534A0 (es)
MA (1) MA34845B1 (es)
MX (1) MX2013008870A (es)
PE (1) PE20141012A1 (es)
SG (1) SG192216A1 (es)
TN (1) TN2013000323A1 (es)
UY (1) UY33889A (es)
WO (1) WO2012104206A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289881A1 (de) * 2009-08-06 2011-03-02 Boehringer Ingelheim International GmbH Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen
EP2670736B1 (de) 2011-02-01 2017-03-15 Boehringer Ingelheim International GmbH 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-chinazolin-6- yloxy]-1,4-diaza-spiro[5.5]undecan-5-on dimaleat, dessen verwendung als arzneimittel und dessen herstellung
AU2013218119A1 (en) * 2012-02-09 2014-07-17 Boehringer Ingelheim International Gmbh Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro [5.5] undecanes
EP2875020B1 (en) 2012-07-19 2017-09-06 Boehringer Ingelheim International GmbH Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one
CA2933082C (en) 2013-12-12 2018-06-26 Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd Quinazoline derivative
CN105017164A (zh) * 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 含新型苯并喹唑啉和邻位氯结构的酪氨酸激酶抑制剂及用途
CN105130913A (zh) * 2015-08-25 2015-12-09 佛山市赛维斯医药科技有限公司 一类多取代的苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN109608470A (zh) * 2018-12-17 2019-04-12 上海药明康德新药开发有限公司 叔丁基-9-氧亚基-2,5,8-三氮杂螺[3.5]壬烷-2-甲酸基酯的合成方法
CN109503579A (zh) * 2018-12-17 2019-03-22 天津药明康德新药开发有限公司 叔丁基-1-甲基-5-氧亚基三氮杂螺[5.5]十一烷-9-甲酸基酯的制备方法
CN109485648A (zh) * 2018-12-17 2019-03-19 无锡合全药业有限公司 叔丁基-1-甲基-5-氧亚基三氮杂螺[5.5]十一烷-8-甲酸基酯的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
EA009300B1 (ru) 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
JP2008513476A (ja) 2004-09-17 2008-05-01 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド c−Kit癌原遺伝子阻害剤としての(スピロシクリルアミド)アミノチオフェン化合物
JP2009518450A (ja) 2005-12-12 2009-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式複素環化合物、その化合物を含む薬剤、その使用及び製造方法
TWI421070B (zh) 2007-10-26 2014-01-01 Japan Tobacco Inc 螺化合物及其醫藥用途
EP2245026B1 (de) * 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
JP2012501991A (ja) * 2008-09-03 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルス性疾患の治療のためのキナゾリン誘導体の使用
EP2289881A1 (de) 2009-08-06 2011-03-02 Boehringer Ingelheim International GmbH Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen
EP2670736B1 (de) 2011-02-01 2017-03-15 Boehringer Ingelheim International GmbH 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-chinazolin-6- yloxy]-1,4-diaza-spiro[5.5]undecan-5-on dimaleat, dessen verwendung als arzneimittel und dessen herstellung

Also Published As

Publication number Publication date
CL2013002031A1 (es) 2013-12-27
NZ613917A (en) 2015-08-28
AR085056A1 (es) 2013-08-07
CN103608336A (zh) 2014-02-26
JP2014504619A (ja) 2014-02-24
US8853225B2 (en) 2014-10-07
MA34845B1 (fr) 2014-01-02
EP2670736A1 (de) 2013-12-11
KR20140011330A (ko) 2014-01-28
US20140371226A1 (en) 2014-12-18
WO2012104206A9 (de) 2013-11-21
AP3531A (en) 2016-01-13
SG192216A1 (en) 2013-09-30
EA023573B1 (ru) 2016-06-30
CO6781555A2 (es) 2013-10-31
WO2012104206A1 (de) 2012-08-09
EP2670736B1 (de) 2017-03-15
CA2826193A1 (en) 2012-08-09
AP2013006989A0 (en) 2013-07-31
BR112013019416A2 (pt) 2019-09-24
US20130030003A1 (en) 2013-01-31
UY33889A (es) 2012-08-31
EA201300872A1 (ru) 2014-01-30
GEP20156423B (en) 2016-01-11
US8906931B1 (en) 2014-12-09
TN2013000323A1 (en) 2015-01-20
MX2013008870A (es) 2013-08-14
ECSP13012847A (es) 2014-09-30
IL227534A0 (en) 2013-09-30
AU2012213556A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
PE20141012A1 (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
CL2013002474A1 (es) Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras.
IN2014DN09434A (es)
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
CL2008003480A1 (es) Compuestos derivados de amino-pirimidina, con propiedades inmunomoduladoras y que actuan a traves de tlr7; proceso para preparar los compuestos; compuestos intermediarios; composicion y combinacion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
ES2446643R1 (es) Composiciones farmacéuticas combinadas y su uso para preparar un medicamento destinado al tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular
CL2015002835A1 (es) Nuevos derivados de piridina
BR112014011981B8 (pt) Formulações farmacêuticas sólidas orais, seus processos de preparação e usos
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
AR085998A1 (es) Aclidinio y su uso en la mejora de la calidad del sueño
BR112015028890A2 (pt) derivados de piridona para o tratamento de infecções virais e outras doenças

Legal Events

Date Code Title Description
FA Abandonment or withdrawal